Equities

Esperion Therapeutics Inc

Esperion Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.28
  • Today's Change0.17 / 8.06%
  • Shares traded8.95m
  • 1 Year change+130.09%
  • Beta0.9379
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

  • Revenue in USD (TTM)295.45m
  • Net income in USD-86.77m
  • Incorporated2008
  • Employees240.00
  • Location
    Esperion Therapeutics Inc3891 Ranchero DriveSuite 150, Suite 300ANN ARBOR 32960United StatesUSA
  • Phone+1 (734) 887-3903
  • Fax+1 (302) 655-5049
  • Websitehttps://www.esperion.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Precigen Inc4.39m-135.38m278.63m202.00--5.71--63.48-0.5407-0.54070.01760.17090.0313--4.7121,727.72-96.46-31.50-119.34-38.63-13.5644.00-3,084.55-232.32----0.00---76.87-47.16-20.22---48.30--
Sanara Medtech Inc72.41m-6.57m308.24m107.00--7.39--4.26-0.7788-0.77888.624.771.101.868.13676,731.00-10.16-17.73-12.08-22.0789.7388.08-9.23-17.131.49-4.880.2577--41.7761.9345.79--99.09--
Biostem Technologies Inc131.44m7.87m371.35m67.0068.1420.5145.942.830.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Revance Therapeutics Inc247.00m-180.81m385.47m597.00------1.56-1.91-1.952.55-1.550.4971.036.71413,740.40-36.38-55.55-43.47-63.2072.61---73.20-304.963.05-15.401.58--76.55128.849.10---0.3022--
Rigel Pharmaceuticals Inc130.30m-14.23m388.32m147.00------2.98-0.8136-0.81367.45-1.701.061.055.24886,401.40-11.59-28.82-19.93-47.2692.4197.88-10.92-35.761.48-1.732.00---2.7921.3057.16--68.45--
Theravance Biopharma Inc62.02m-45.65m437.36m99.00--2.26--7.05-0.924-0.9241.253.960.1534--4.12626,434.30-11.29-40.51-12.00-48.50-----73.61-305.27----0.1305--11.84-0.995640.54---19.24--
Esperion Therapeutics Inc295.45m-86.77m447.39m240.00------1.51-0.6585-0.65851.72-1.891.100.82755.351,231,046.00-32.41-69.45-74.85-101.8181.58---29.37-147.441.370.3253----54.14--10.45------
Amylyx Pharmaceuticals Inc298.76m-165.87m456.15m384.00--1.75--1.53-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Zevra Therapeutics Inc23.99m-65.75m473.56m65.00--11.64--19.74-1.67-1.670.61060.77340.1919--2.09369,015.40-52.61-32.11-65.34-39.8971.78---274.10-128.42---112.940.6423--170.26---72.00--69.75--
Aquestive Therapeutics Inc58.36m-25.72m497.83m135.00------8.53-0.3565-0.35650.7874-0.38960.66852.857.25432,296.30-29.46-76.63-42.14-123.8568.4964.24-44.07-102.956.98-2.67----6.09-5.5985.54---11.42--
Xeris Biopharma Holdings Inc181.41m-59.56m517.03m377.00------2.85-0.4215-0.42151.28-0.12950.54930.74284.99481,201.60-18.04-43.60-23.57-56.5783.7278.23-32.83-143.081.69-1.591.09--48.68131.5034.23--8.43--
SNDL Inc655.68m-81.17m525.69m2.52k--0.5927--0.8018-0.3107-0.31072.503.340.59884.6333.15260,604.80-7.67-24.44-8.32-27.9425.0422.49-12.82-62.172.98--0.1125--27.63--49.83------
SIGA Technologies Inc172.96m83.97m540.27m45.006.513.226.393.121.161.162.412.351.020.586623.093,843,484.0049.5222.3456.2127.5682.0088.6548.5541.145.65--0.0029.5126.31-21.75100.76-30.57-26.67--
Elite Pharmaceuticals Inc66.45m19.58m544.61m64.0026.659.3525.868.200.01910.01910.0640.05450.98922.914.981,038,252.0029.1519.0736.1824.2945.2746.6329.4720.772.091.440.13890.0065.7949.55464.56--111.50--
ASP Isotopes Inc2.30m-27.05m599.95m76.00--41.52--261.34-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Data as of Nov 08 2024. Currency figures normalised to Esperion Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

41.74%Per cent of shares held by top holders
HolderShares% Held
Wasatch Advisors LPas of 30 Jun 202416.86m8.59%
The Vanguard Group, Inc.as of 30 Sep 202413.04m6.65%
BlackRock Fund Advisorsas of 30 Jun 202412.93m6.59%
Bellevue Asset Management AGas of 30 Jun 20249.94m5.07%
Great Point Partners LLCas of 30 Jun 20245.79m2.95%
Two Seas Capital LPas of 30 Jun 20245.74m2.92%
Woodline Partners LPas of 30 Jun 20245.05m2.57%
Marshall Wace LLPas of 30 Jun 20244.30m2.19%
Geode Capital Management LLCas of 30 Jun 20244.16m2.12%
Two Sigma Investments LPas of 30 Jun 20244.07m2.08%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.